Amphastar Pharmaceuticals AMPH Income Statement (2013-2026)

NASDAQ AMPH
$29.38 +0.89 (+3.12%)
At close: Nov 9, 2026 · 4:00 PM EST
Reported Financials

Amphastar Pharmaceuticals Quarterly Income Statement

Periods 54 quarters
Latest Sep 2026

Amphastar Pharmaceuticals reported revenue of $207.61M and net income of $37.76M for the quarter ended Sep 2026, up 8.2% year over year. This income statement covers 54 quarters of results from Jun 2013 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Income StatementIncome Statement Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Revenue & cost
Revenue
120.89M120.37M123.47M120.13M135.02M140.02M145.71M180.56M178.11M171.84M182.39M191.21M186.52M170.53M174.41M191.84M183.11M171.17M183.90M207.61M
Cost of RevenueCost of Rev
64.65M64.54M60.11M61.62M63.86M66.18M72.97M72.15M81.97M81.74M87.23M89.27M99.88M85.28M87.92M93.19M97.44M100.85M90.43M107.98M
Gross Profit
56.23M55.83M63.36M58.51M71.17M73.84M72.74M108.40M96.14M90.10M95.17M101.94M86.65M85.25M86.49M98.65M85.67M70.32M93.47M99.63M
Operating items
Research & DevelopmentR&D
17.29M16.22M22.80M18.51M17.24M19.82M16.84M16.66M20.42M17.04M17.65M21.08M18.14M20.10M20.08M22.35M23.31M26.74M22.16M20.08M
Share-based Compensation (IS)Stock Comp.
7.36M5.78M5.60M5.63M8.39M6.38M6.30M6.21M9.27M7.09M7.01M
Selling, General & AdministrativeSG&A
10.62M12.47M9.98M11.98M10.63M13.48M12.28M12.65M13.12M15.68M13.29M14.82M12.94M16.00M13.99M39.47M16.47M18.03M18.24M16.84M
Other Operating ExpensesOther Opex
4.08M5.52M5.76M4.78M5.47M7.11M6.72M6.41M8.62M9.37M9.01M9.00M10.42M11.87M10.24M11.51M10.28M11.93M13.34M11.93M
Operating ExpensesOpex
31.98M34.21M38.53M35.28M33.34M40.41M35.84M35.73M42.16M42.09M39.95M44.89M41.50M47.96M44.31M73.33M50.06M56.69M53.74M48.86M
Operating IncomeOp. Inc
24.25M21.61M24.82M23.23M37.83M33.43M36.90M72.68M53.98M48.01M55.22M57.05M45.14M37.29M42.18M25.32M35.61M13.63M39.73M50.77M
Non-operating items
Non Operating Interest Expenses
0.17M0.36M0.40M0.57M0.53M0.40M3.60M13.70M9.46M8.61M8.61M6.70M6.43M6.29M6.28M6.28M6.63M6.55M6.66M6.76M
Gains (Losses) on Sale of Assets & InvestmentsGains on Sales
Interest & Investment IncomeInt & Inv Inc
0.16M0.18M0.23M0.33M0.58M0.92M1.03M1.20M2.30M2.56M3.34M2.43M2.29M2.09M1.92M2.25M2.42M2.40M2.29M2.29M
Other Non Operating IncomeOther Non Op Inc.
2.92M7.59M-1.50M-0.40M3.38M-0.39M-1.52M3.46M-5.48M5.92M0.30M-5.09M2.95M-2.23M1.51M0.23M0.52M0.58M3.19M2.76M
Non Operating IncomeNon Op. Inc.
2.91M7.42M-1.67M-0.63M3.43M0.14M-4.09M-9.04M-12.64M-0.13M-4.97M-9.37M-1.18M-6.43M-2.85M-3.81M-3.69M-3.58M-1.19M-1.71M
Net income details
EBIT
24.25M21.61M24.82M23.23M37.83M33.43M36.90M72.68M53.98M48.01M55.22M57.05M45.14M37.29M42.18M25.32M35.61M13.63M39.73M50.77M
EBT
27.16M29.03M23.15M22.60M41.26M33.57M32.81M63.64M41.35M47.88M50.24M47.68M43.96M30.86M39.34M21.51M31.91M10.05M38.54M49.06M
Tax ProvisionsTaxes
7.19M4.08M5.55M6.56M7.29M6.75M6.38M14.03M4.67M4.13M12.29M7.25M6.00M5.58M8.31M4.16M7.49M3.63M8.20M11.30M
Income After Tax
19.97M24.96M17.60M16.04M33.97M26.82M26.43M49.61M36.67M43.75M37.95M40.43M37.96M25.29M31.03M17.35M24.43M6.42M30.35M37.76M
Equity Income
-0.70M-0.25M-0.16M-0.06M-0.79M-0.30M-0.39M-0.51M-0.57M
Income from Continuing OperationsIncome (Continuing)
19.97M24.96M17.60M16.04M33.97M26.82M26.43M49.61M36.67M43.75M37.95M40.43M37.96M25.29M31.03M17.35M24.43M6.42M30.35M37.76M
Consolidated Net IncomeConsol Net Inc.
19.76M24.25M17.35M15.87M33.91M26.03M26.12M49.22M36.17M43.18M37.95M40.43M37.96M25.29M31.03M17.35M24.43M6.42M30.35M37.76M
Net Income Attributable to Noncontrolling InterestsNCI Net Income
Income towards Parent CompanyParent Net Inc
19.76M24.25M17.35M15.87M33.91M26.03M26.12M49.22M36.17M43.18M37.95M40.43M37.96M25.29M31.03M17.35M24.43M6.42M30.35M37.76M
Net Income towards Common StockholdersNet Income
19.76M24.25M17.35M15.87M33.91M26.03M26.12M49.22M36.17M43.18M37.95M40.43M37.96M25.29M31.03M17.35M24.43M6.42M30.35M37.76M
Additional items
EPS (Basic)
0.410.500.350.320.700.540.541.010.750.900.780.830.780.530.660.370.520.140.700.89
EPS (Diluted)
0.400.470.330.300.650.500.490.910.680.810.730.780.730.510.640.360.510.140.690.87
Shares Outstanding
47.78M48.14M48.86M48.90M48.55M48.00M48.40M48.70M48.27M48.21M48.91M48.62M48.43M47.64M46.95M46.47M46.74M45.32M43.64M42.58M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
49.78M51.98M53.23M52.79M52.43M51.97M53.10M53.92M53.00M53.01M52.05M51.86M52.06M49.89M48.13M47.68M48.22M46.46M44.23M43.38M
Shares Outstanding (Entity)Shares Outstanding (Entity.)
47.71M48.75M48.99M48.61M48.11M48.18M48.82M47.90M48.07M48.84M48.96M48.37M47.62M47.67M46.49M46.35M45.65M44.64M42.53M42.65M
EBITDA
26.99M24.71M27.97M27.12M41.52M37.13M43.38M93.71M72.73M65.97M73.52M73.76M59.30M51.66M57.64M40.33M50.81M28.74M54.92M67.33M
Interest ExpensesInt Expense
0.17M0.36M0.40M0.57M0.53M0.40M3.60M13.70M9.46M8.61M8.61M6.70M6.43M6.29M6.28M6.28M6.63M6.55M6.66M6.76M
Tax Rate
26.49%14.04%23.98%29.03%17.67%20.11%19.46%22.04%11.30%8.62%24.47%15.21%13.64%18.07%21.11%19.35%23.45%36.13%21.26%23.03%

Amphastar Pharmaceuticals Income Statement API

Pull Amphastar Pharmaceuticals's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=AMPH&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY